Operational focus is shifting toward high-volume specialists in cardiology and endocrinology to prepare for the first independent launch in a broad patient population.The transition to a fully integrated commercial biotech is supported by a diversified revenue model that balances independent launches with a high-value partner pipeline.DAWNZERA's early launch trajectory is characterized by high conversion rates from free trials and adoption across switch, treatment-naive, and on-demand patient segments.The c ...